---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-004543"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T06:04:52.491652+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma raises $2M via 8% OID debentures with 790K incentive shares

## Summary
- Issued $2,173,913 principal of 8% OID debentures for $2,000,000; maturity sooner of 90 days or $8M financing event.
- Debentures are non-convertible, bear no interest; 790,000 shares of common stock issued as incentive shares.
- Proceeds to be used for debt repayment and working capital; offering exempt under Section 4(a)(2).

## SEC filing metadata
- accession: 0001493152-26-004543
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315226004543/0001493152-26-004543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315226004543/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-004543
- JSON: https://secwatch.observer/filing/0001493152-26-004543.json
- Plain text: https://secwatch.observer/filing/0001493152-26-004543.txt

## Key facts
- Material Agreements
  Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain investors (the “Purchasers”) valued at aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000 (effective 2026-01-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors (the “Purchasers”)
  - Value: aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000
  - Effective: 2026-01-26
  source text: On January 26, 2026, Aspire Biopharma Holdings, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers certain debentures in an aggregate principal amount of $2,173,913.04 for a subscription price of $2,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315226004543/0001493152-26-004543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.